Precision Ocular Metrology: Precision Ocular nets £13.5M to go after indications contested by Regeneron, Roche

Precision Ocular has raised £13.5 million ($18.9 million) to develop a pipeline of retinal disease drugs and accompanying minimally invasive delivery technologies. Retinal vein occlusion, diabetic macular edema and age-related macular degeneration top the list of indications being pursued by Precision Ocular, putting Regeneron's Eylea and Roche's Lucentis squarely in its sights.